BIOMAT Database Logo BIOMAT Database Logo

[Elevated immunosuppressive acidic protein in patients with subacute thyroiditis]. 1982

H Fukazawa, and T Sakurada, and K Tamura, and M Yamamoto, and K Yoshida, and H Kitaoka, and N Kaise, and K Kaise, and M Suzuki, and S Saito, and K Yoshinaga, and N Ishida

UI MeSH Term Description Entries
D006980 Hyperthyroidism Hypersecretion of THYROID HORMONES from the THYROID GLAND. Elevated levels of thyroid hormones increase BASAL METABOLIC RATE. Hyperthyroid,Primary Hyperthyroidism,Hyperthyroidism, Primary,Hyperthyroids
D007037 Hypothyroidism A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA. It may be primary or secondary due to other pituitary disease, or hypothalamic dysfunction. Central Hypothyroidism,Primary Hypothyroidism,Secondary Hypothyroidism,TSH Deficiency,Thyroid-Stimulating Hormone Deficiency,Central Hypothyroidisms,Deficiency, TSH,Deficiency, Thyroid-Stimulating Hormone,Hormone Deficiency, Thyroid-Stimulating,Hypothyroidism, Central,Hypothyroidism, Primary,Hypothyroidism, Secondary,Hypothyroidisms,Primary Hypothyroidisms,Secondary Hypothyroidisms,TSH Deficiencies,Thyroid Stimulating Hormone Deficiency,Thyroid-Stimulating Hormone Deficiencies
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013966 Thyroiditis Inflammatory diseases of the THYROID GLAND. Thyroiditis can be classified into acute (THYROIDITIS, SUPPURATIVE), subacute (granulomatous and lymphocytic), chronic fibrous (Riedel's), chronic lymphocytic (HASHIMOTO DISEASE), transient (POSTPARTUM THYROIDITIS), and other AUTOIMMUNE THYROIDITIS subtypes. Thyroiditides
D013972 Thyrotropin A glycoprotein hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Thyrotropin stimulates THYROID GLAND by increasing the iodide transport, synthesis and release of thyroid hormones (THYROXINE and TRIIODOTHYRONINE). Thyrotropin consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the pituitary glycoprotein hormones (TSH; LUTEINIZING HORMONE and FSH), but the beta subunit is unique and confers its biological specificity. Thyroid-Stimulating Hormone,TSH (Thyroid Stimulating Hormone),Thyreotropin,Thyrotrophin,Hormone, Thyroid-Stimulating,Thyroid Stimulating Hormone
D013974 Thyroxine The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism. L-Thyroxine,Levothyroxine,T4 Thyroid Hormone,3,5,3',5'-Tetraiodothyronine,Berlthyrox,Dexnon,Eferox,Eltroxin,Eltroxine,Euthyrox,Eutirox,L-3,5,3',5'-Tetraiodothyronine,L-Thyrox,L-Thyroxin Henning,L-Thyroxin beta,L-Thyroxine Roche,Levo-T,Levothroid,Levothyroid,Levothyroxin Deladande,Levothyroxin Delalande,Levothyroxine Sodium,Levoxine,Levoxyl,Lévothyrox,Novothyral,Novothyrox,O-(4-Hydroxy-3,5-diiodophenyl) 3,5-diiodo-L-tyrosine,O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodotyrosine,Oroxine,Sodium Levothyroxine,Synthroid,Synthrox,Thevier,Thyrax,Thyroxin,Tiroidine,Tiroxina Leo,Unithroid,L Thyrox,L Thyroxin Henning,L Thyroxin beta,L Thyroxine,L Thyroxine Roche,Levo T,Thyroid Hormone, T4
D014284 Triiodothyronine A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3. Liothyronine,T3 Thyroid Hormone,3,3',5-Triiodothyronine,Cytomel,Liothyronine Sodium,Thyroid Hormone, T3

Related Publications

H Fukazawa, and T Sakurada, and K Tamura, and M Yamamoto, and K Yoshida, and H Kitaoka, and N Kaise, and K Kaise, and M Suzuki, and S Saito, and K Yoshinaga, and N Ishida
Immunosuppressive acidic protein in patients with testicular cancer.
January 1987, The Journal of urology,
H Fukazawa, and T Sakurada, and K Tamura, and M Yamamoto, and K Yoshida, and H Kitaoka, and N Kaise, and K Kaise, and M Suzuki, and S Saito, and K Yoshinaga, and N Ishida
Immunosuppressive acidic protein in patients with lung cancer.
November 1992, Chest,
H Fukazawa, and T Sakurada, and K Tamura, and M Yamamoto, and K Yoshida, and H Kitaoka, and N Kaise, and K Kaise, and M Suzuki, and S Saito, and K Yoshinaga, and N Ishida
Immunosuppressive acidic protein in patients with ovarian cancer.
December 1983, Cancer,
H Fukazawa, and T Sakurada, and K Tamura, and M Yamamoto, and K Yoshida, and H Kitaoka, and N Kaise, and K Kaise, and M Suzuki, and S Saito, and K Yoshinaga, and N Ishida
Immunosuppressive acidic protein in patients with gynecologic cancer.
August 1984, Cancer,
H Fukazawa, and T Sakurada, and K Tamura, and M Yamamoto, and K Yoshida, and H Kitaoka, and N Kaise, and K Kaise, and M Suzuki, and S Saito, and K Yoshinaga, and N Ishida
[Immunosuppressive acidic protein in patients with gynecologic cancer].
May 1983, Nihon Sanka Fujinka Gakkai zasshi,
H Fukazawa, and T Sakurada, and K Tamura, and M Yamamoto, and K Yoshida, and H Kitaoka, and N Kaise, and K Kaise, and M Suzuki, and S Saito, and K Yoshinaga, and N Ishida
[Patients with subacute thyroiditis].
October 1971, Nederlands tijdschrift voor geneeskunde,
H Fukazawa, and T Sakurada, and K Tamura, and M Yamamoto, and K Yoshida, and H Kitaoka, and N Kaise, and K Kaise, and M Suzuki, and S Saito, and K Yoshinaga, and N Ishida
[Immunosuppressive acidic protein levels in patients with gynecologic malignancy].
December 1982, Nihon Gan Chiryo Gakkai shi,
H Fukazawa, and T Sakurada, and K Tamura, and M Yamamoto, and K Yoshida, and H Kitaoka, and N Kaise, and K Kaise, and M Suzuki, and S Saito, and K Yoshinaga, and N Ishida
Mean Platelet Volume and Platelet Count are Elevated in Patients with Subacute Thyroiditis.
September 2017, Clinical laboratory,
H Fukazawa, and T Sakurada, and K Tamura, and M Yamamoto, and K Yoshida, and H Kitaoka, and N Kaise, and K Kaise, and M Suzuki, and S Saito, and K Yoshinaga, and N Ishida
[Serum immunosuppressive acidic protein (IAP) in patients with hematological disorders].
December 1986, Rinsho byori. The Japanese journal of clinical pathology,
H Fukazawa, and T Sakurada, and K Tamura, and M Yamamoto, and K Yoshida, and H Kitaoka, and N Kaise, and K Kaise, and M Suzuki, and S Saito, and K Yoshinaga, and N Ishida
Immunosuppressive acidic protein (IAP) in gastric cancer patients.
July 1983, The Japanese journal of surgery,
Copied contents to your clipboard!